微小RNA在与BRCA1突变相关的乳腺癌和卵巢癌治疗中的潜在作用。
The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation.
作者信息
Strumidło Agnieszka, Skiba Sylwia, Scott Rodney J, Lubiński Jan
机构信息
Pomeranian University of Medicine, Szczecin, Poland.
The University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia.
出版信息
Hered Cancer Clin Pract. 2017 Sep 29;15:15. doi: 10.1186/s13053-017-0076-7. eCollection 2017.
Abstract
Germline variants within BRCA1 or BRCA2 genes account for approximately 25% of familial aggregations of breast-ovarian cancers. Low or no expression of BRCA1 in breast and ovarian cancers is associated with a good clinical response to treatment with platinum therapies and PARP1 inhibitors. Recent studies demonstrated that microRNAs - small non-coding RNAs, involved in the control of gene expression, can decrease BRCA1 expression by targeting the 3'UTR region of the gene. This article reviews reported relationships between various miRNAs, such as miRNA-9, miRNA-146a, miRNA-182 miRNA-218, miRNA-638 and the response to cytostatic drugs, mainly to platins and PARP1 inhbitors, for the treatment of breast and ovarian cancer associated with BRCA1 mutations.
摘要
BRCA1或BRCA2基因中的种系变异约占乳腺-卵巢癌家族聚集病例的25%。乳腺癌和卵巢癌中BRCA1低表达或无表达与铂类疗法及PARP1抑制剂治疗的良好临床反应相关。最近的研究表明，微小RNA（参与基因表达调控的小型非编码RNA）可通过靶向该基因的3'UTR区域降低BRCA1的表达。本文综述了已报道的各种微小RNA（如miRNA-9、miRNA-146a、miRNA-182、miRNA-218、miRNA-638）与细胞毒性药物（主要是铂类和PARP1抑制剂）治疗BRCA1突变相关乳腺癌和卵巢癌的反应之间的关系。
相似文献
1
The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation.微小RNA在与BRCA1突变相关的乳腺癌和卵巢癌治疗中的潜在作用。
Hered Cancer Clin Pract. 2017 Sep 29;15:15. doi: 10.1186/s13053-017-0076-7. eCollection 2017.
2
Genetic Variants in the 3'UTR of and Genes and their Putative Effects on the microRNA Mechanism in Hereditary Breast and Ovarian Cancer.与遗传性乳腺癌和卵巢癌相关的基因3'非翻译区中的遗传变异及其对微小RNA机制的潜在影响。
Diagnostics (Basel). 2020 May 13;10(5):298. doi: 10.3390/diagnostics10050298.
3
Association between hsa-mir-146a genotype and tumor age-of-onset in BRCA1/BRCA2-negative familial breast and ovarian cancer patients.BRCA1/BRCA2 阴性家族性乳腺癌和卵巢癌患者中 hsa-mir-146a 基因型与肿瘤发病年龄的相关性。
Carcinogenesis. 2010 Dec;31(12):2124-6. doi: 10.1093/carcin/bgq184. Epub 2010 Sep 1.
4
Evaluation of genetic variations in miRNA-binding sites of BRCA1 and BRCA2 genes as risk factors for the development of early-onset and/or familial breast cancer.评估BRCA1和BRCA2基因的miRNA结合位点的遗传变异作为早发性和/或家族性乳腺癌发生风险因素的情况。
Asian Pac J Cancer Prev. 2014;15(19):8319-24. doi: 10.7314/apjcp.2014.15.19.8319.
5
Two novel variants in the 3'UTR of the BRCA1 gene in familial breast and/or ovarian cancer.BRCA1 基因 3'UTR 中的两个新变异与家族性乳腺癌和/或卵巢癌相关。
Breast Cancer Res Treat. 2011 Feb;125(3):885-91. doi: 10.1007/s10549-010-1165-8. Epub 2010 Sep 17.
6
Identification of fifteen novel germline variants in the BRCA1 3'UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site.鉴定 BRCA1 3'UTR 中的十五个新种系变体，揭示了一个乳腺癌病例中的变体，该变体引入了功能性 miR-103 靶位。
Hum Mutat. 2012 Dec;33(12):1665-75. doi: 10.1002/humu.22159. Epub 2012 Aug 2.
7
Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.来自一家乳腺癌风险评估诊所的乳腺-卵巢癌家族中BRCA1和BRCA2的种系突变。
J Clin Oncol. 2001 Apr 15;19(8):2247-53. doi: 10.1200/JCO.2001.19.8.2247.
8
The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2.BRCA1/2导向的miRNA特征预示着野生型BRCA1/2的卵巢癌患者预后良好。
Oncotarget. 2015 Feb 10;6(4):2397-406. doi: 10.18632/oncotarget.2963.
9
A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis.miR-146a基因中的功能性多态性与家族性乳腺癌/卵巢癌诊断年龄
Carcinogenesis. 2008 Oct;29(10):1963-6. doi: 10.1093/carcin/bgn172. Epub 2008 Jul 27.
引用本文的文献
1
Strategy for Pre-Clinical Development of Active Targeting MicroRNA Oligonucleotide Therapeutics for Unmet Medical Needs.针对未满足医疗需求的主动靶向 microRNA 寡核苷酸治疗药物的临床前开发策略。
Int J Mol Sci. 2023 Apr 12;24(8):7126. doi: 10.3390/ijms24087126.
2
Prognostic and Predictive Biomarkers in Familial Breast Cancer.家族性乳腺癌的预后和预测生物标志物
Cancers (Basel). 2023 Feb 20;15(4):1346. doi: 10.3390/cancers15041346.
3
Enhanced ZNF521 expression induces an aggressive phenotype in human ovarian carcinoma cell lines.增强 ZNF521 的表达可诱导人卵巢癌细胞系呈现侵袭表型。
PLoS One. 2022 Oct 3;17(10):e0274785. doi: 10.1371/journal.pone.0274785. eCollection 2022.
4
Identification of high expression profiles of miR-31-5p and its vital role in lung squamous cell carcinoma: a survey based on qRT-PCR and bioinformatics analysis.miR-31-5p高表达谱的鉴定及其在肺鳞状细胞癌中的重要作用：基于qRT-PCR和生物信息学分析的研究
Transl Cancer Res. 2019 Jun;8(3):788-801. doi: 10.21037/tcr.2019.04.21.
5
Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review.铂类和紫杉烷类辅助及新辅助化疗用于早期三阴性乳腺癌：一项叙述性综述
Front Pharmacol. 2021 Dec 6;12:770663. doi: 10.3389/fphar.2021.770663. eCollection 2021.
6
Recent Advances in miRNA Delivery Systems.微小RNA递送系统的最新进展
Methods Protoc. 2021 Jan 20;4(1):10. doi: 10.3390/mps4010010.
7
Efficient Delivery of MicroRNA and AntimiRNA Molecules Using an Argininocalix[4]arene Macrocycle.使用精氨酸杯[4]芳烃大环高效递送微小RNA和抗微小RNA分子。
Mol Ther Nucleic Acids. 2019 Dec 6;18:748-763. doi: 10.1016/j.omtn.2019.09.029. Epub 2019 Oct 11.
8
The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer.散发性卵巢癌中的 BRCA1 甲基化和 PD-L1 表达。
Int J Gynecol Cancer. 2018 Oct;28(8):1514-1519. doi: 10.1097/IGC.0000000000001334.
9
Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors.乳腺癌细胞系中微小RNA与药物相互作用的筛选表明miR-126是细胞周期蛋白依赖性激酶4/6（CDK4/6）和磷脂酰肌醇-4,5-二磷酸3-激酶催化亚基α（PIK3CA）抑制剂的调节剂。
Front Genet. 2018 May 18;9:174. doi: 10.3389/fgene.2018.00174. eCollection 2018.
本文引用的文献
1
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.用于BRCA1/2突变型和散发性卵巢癌的PARP抑制剂：当前实践与未来方向
Br J Cancer. 2016 Nov 8;115(10):1157-1173. doi: 10.1038/bjc.2016.311. Epub 2016 Oct 13.
2
MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.三阴性乳腺癌中MicroRNA失调揭示了miR-498在调节BRCA1表达中的作用。
Oncotarget. 2016 Apr 12;7(15):20068-79. doi: 10.18632/oncotarget.7705.
3
miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival.BRCA1 缺陷型三阴性乳腺癌肿瘤中的 miR-146a 和 miR-638，作为改善总体生存的潜在生物标志物。
Cancer Biomark. 2016;16(1):99-107. doi: 10.3233/CBM-150545.
4
miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.BRCA1和BRCA2种系突变携带者的正常乳腺组织及浸润性乳腺癌中的miRNA表达模式。
Oncotarget. 2015 Oct 13;6(31):32115-37. doi: 10.18632/oncotarget.5617.
5
An update on PARP inhibitors for the treatment of cancer.PARP抑制剂治疗癌症的最新进展。
Onco Targets Ther. 2015 Feb 26;8:519-28. doi: 10.2147/OTT.S30793. eCollection 2015.
6
The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2.BRCA1/2导向的miRNA特征预示着野生型BRCA1/2的卵巢癌患者预后良好。
Oncotarget. 2015 Feb 10;6(4):2397-406. doi: 10.18632/oncotarget.2963.
7
MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.微小RNA-218通过靶向乳腺癌1号基因（BRCA1）来调节乳腺癌对顺铂的化疗敏感性。
Tumour Biol. 2015 Mar;36(3):2065-75. doi: 10.1007/s13277-014-2814-z. Epub 2014 Nov 15.
8
miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer.miR-638介导的BRCA1调控影响三阴性乳腺癌的DNA修复以及对紫外线和顺铂的敏感性。
Breast Cancer Res. 2014 Sep 17;16(5):435. doi: 10.1186/s13058-014-0435-5.
9
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.全球癌症发病与死亡：GLOBOCAN 2012 数据源、方法与主要模式。
Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.
10
Cisplatin in cancer therapy: molecular mechanisms of action.顺铂在癌症治疗中的作用：分子作用机制
Eur J Pharmacol. 2014 Oct 5;740:364-78. doi: 10.1016/j.ejphar.2014.07.025. Epub 2014 Jul 21.
Zotero 插件